Details

Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
ID Ruiz-López, Eduardo (Author), ID Jovchevska, Ivana (Author), ID Schuhmacher, Alberto J. (Author), et al.

.pdfPDF - Presentation file, Download (3,75 MB)
MD5: 7B67331F8C6054C442BD8C039522F155
URLURL - Source URL, Visit https://www.nature.com/articles/s41598-022-27161-3 This link opens in a new window

Abstract
The cancer "omics" reveal many clinically relevant alterations that are transforming the molecular characterization of glioblastomas. However, many of these findings are not yet translated into clinical practice due, in part, to the lack of non-invasive biomarkers and the limitations imposed by the blood-brain barrier. Nanobodies, camelid single-domain antibody fragments, emerge as a promising tool for immunotargeted applications for diagnosing and treating glioblastomas. Performing agnostic bioinformatic analysis from glioblastoma patient datasets, we identified ATP Binding Cassette subfamily C member 3 (ABCC3) as a suitable target for immunotargeted applications. The expression of ABCC3 is associated with poor survival and impaired response to temozolomide. Importantly, high expression of ABCC3 is restricted to glioblastoma, with negligible levels in healthy brain tissue, and further correlates with tumor grade and stemness markers. We identified three immunogenic epitopes of ABCC3 which were used to isolate nanobodies from a glioblastoma-specific phage-display nanobody library. Two nanobodies targeting ABCC3 (NbA42 and NbA213) were further characterized and demonstrated in vivo selective recognition of ABCC3 in glioblastoma xenograft mouse models upon systemic administration. We designate NbA42 and NbA213 as new candidates to implement immunotargeted applications guiding a more personalized and precise diagnosis, monitoring, and treatment of glioblastoma patients.

Language:English
Keywords:glioblastoma, nanobodies, immunotargeted applications, antibody fragment therapy, biologics, CNS cancer
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:12 str.
Numbering:Vol. 12, art. 22581
PID:20.500.12556/RUL-165165 This link opens in a new window
UDC:616-006
ISSN on article:2045-2322
DOI:10.1038/s41598-022-27161-3 This link opens in a new window
COBISS.SI-ID:136531971 This link opens in a new window
Publication date in RUL:26.11.2024
Views:696
Downloads:414
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Scientific reports
Shortened title:Sci. rep.
Publisher:Springer Nature
ISSN:2045-2322
COBISS.SI-ID:18727432 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:glioblastom, nanotelesa, imunsko usmerjene aplikacije

Projects

Funder:Instituto de Salud Carlos III
Funding programme:Fondo de Investigación en Salud
Project number:PI18/01665

Funder:Instituto de Salud Carlos III
Funding programme:Fondo de Investigación en Salud
Project number:PI21/00441

Funder:EC - European Commission
Funding programme:ERDF, A way to make Europe

Funder:Fundación FERO
Funding programme:XIII Beca FERO en Investigación Oncológica Traslacional

Funder:ASPANOA - Asociación de Padres de Niños con Cáncer de Aragón
Funding programme:Ayudas a la investigación del cáncer infantil

Funder:Other - Other funder or multiple funders
Funding programme:Proyectos líneas prioritarias y de carácter multidisciplinar de la RIS3 2021–2023 DGA
Project number:LMP248_21

Funder:Asociación Española de Cáncer de Mama Metastásico
Funding programme:Metapremio

Funder:AECC - Asociación Española Contra el Cáncer
Funding programme:Ayuda Predoctoral-Aragón

Funder:AECC - Asociación Española Contra el Cáncer
Funding programme:Fundación Científica
Project number:PRDAR17002RUIZ

Funder:Other - Other funder or multiple funders
Funding programme:Ibercaja-CAI Research Fellowships program
Project number:CM 5/19

Funder:ARRS - Slovenian Research Agency
Project number:Z3-1869
Name:Razvoj anti-FREM2 nanotelesa in njegova uporaba pri ciljanju glioblastomskih celic

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back